Alcresta Therapeutics is a high-growth medical device company that sells RELiZORB, an FDA-cleared device that is attached to feeding tubes to help break down fats in enteral formula. RELiZORB has a broad indication for addressing fat malabsorption in tube-fed patients across a variety of disease states, including cystic fibrosis, short bowel syndrome, pancreatitis, and oncology.